 |
|
|||||
Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a progressive neurodegenerative disease for which there is no cure. It affects motor neurons in the brain and spinal cord that control voluntary muscle movement. Progressive degeneration of motor neurons in ALS results in death of motor neurons and loss of voluntary muscle control. Onset of ALS is usually in adulthood and the disease progresses rapidly, starting with generalized muscle weakness and wasting, but ultimately resulting in total paralysis. Average survival after diagnosis is 3 to 5 years, with death usually a result of respiratory complications. The exact causes of ALS are unknown. Most cases are sporadic, but 5-10% of cases are familial. Approximately 30,000 people throughout the U.S. currently have ALS, and 8,000 new cases are diagnosed each year. ALS occurs in individuals of all ages, sexes and races. California Stem Cell began FDA discussions and pre-clinical safety studies for stem cell replacement therapy for ALS in the first quarter of 2008. ALS SupportMDA-ALSMuscular Dystrophy Association’s ALS Division is the world leader among voluntary agencies fighting ALS, offering the most comprehensive range of services. People with ALS receive care at 225 MDA-supported ALS clinical centers across the country. MDA also leads the search for a treatment or cure for ALS through its aggressive, worldwide research program. ALSA ALS Association is the only national not-for-profit health organization dedicated solely to the fight against ALS. The Association leads the way in research, patient and community services, public education, and advocacy — giving help and hope to those facing the disease. The Association’s nationwide network of chapters provides comprehensive patient services and support to the ALS community. |
|
|||||